FHL2 and neoplasm: EpICD associates with β-catenin and cofactor FHL2 (four and a half LIM domain protein 2) to form a transcriptome complex that translocates into the nucleus to modulate the transcriptional activity of target genes, such as c-Myc and promote tumor progression [48].